Peripheral Arterial Disease - Pipeline Review, H1 2012
Feb 27, 2012 - Global Markets Direct - 138 pages
Abstract Table of Contents Request Details Related
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Arterial Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Peripheral Arterial Disease
Peripheral Arterial Disease Therapeutics under Development by Companies
Peripheral Arterial Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Peripheral Arterial Disease Therapeutics - Products under Development by Companies
Peripheral Arterial Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Peripheral Arterial Disease Therapeutics Development
F. Hoffmann-La Roche Ltd.
United Therapeutics Corporation
Sanofi-Aventis
Athersys, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Nissan Chemical Industries, Ltd.
CardioVascular BioTherapeutics, Inc.
MultiGene Vascular Systems (MGVS) Ltd.
Light Sciences Oncology, Inc.
Talecris Biotherapeutics Holdings Corp
Mesoblast Ltd
ReNeuron Group plc
SYGNIS Pharma AG
AnGes MG, Inc.
LTT Bio-Pharma Co., Ltd.
Sucampo Pharmaceuticals, Inc.
7TM Pharma A/S
Biolex Therapeutics, Inc.
Proteon Therapeutics, Inc.
Pervasis Therapeutics, Inc.
Taiwan Liposome Company
Taligen Therapeutics Inc.
Theravasc, Inc.
Viromed Co., Ltd.
Lee's Pharmaceutical Holdings Limited
miRagen Therapeutics, Inc.
Peripheral Arterial Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVBT-141C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK1278863A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPI-017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLX-155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRT-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AX200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Treprostinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aptocine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Peripheral Arterial Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rifalazil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAD Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ReN009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TV1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG1512 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiGeneAngio - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Seaweed Capsule - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DROMOS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAL-05-00018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Collategene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PVS-10200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atorvastatin + Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clopidogrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF + Clopidogrel + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-6114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLTS 934 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF + Aspirin + Clopidogrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NM-702 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Plasminogen activator inhibitor type 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Plasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-Citrulline + Tetrahydrobiopterin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ProFlow - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vasculotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neo-Vessel Replacement - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peripheral Arterial Disease Therapeutics - Drug Profile Updates
Peripheral Arterial Disease Therapeutics - Discontinued Products
Peripheral Arterial Disease Therapeutics - Dormant Products
Peripheral Arterial Disease - Product Development Milestones
Featured News & Press Releases
Jan 24, 2012: Bristol-Myers Squibb And Sanofi Introduce Patient Benefit Program For Plavix
Nov 16, 2011: Triple-Dose Clopidogrel Can Work In People With Genetic Resistance To It, Study Finds
Jun 02, 2011: Cytokinetics Announces Successful Completion Of Phase IIa "evidence of Effect" Clinical Trial Of Ck-2017357, In Patients With Claudication Associated With Peripheral Artery Disease
May 26, 2011: Cytokinetics To Present Clinical Data Of CK-2017357 At 22nd Annual Sessions Of Society For Vascular Medicine
Apr 11, 2011: Cytokinetics To Present Phase IIa Clinical Trial Data Of CK-2017357 In Amyotrophic Lateral Sclerosis At 63rd Annual Meeting Of American Academy of Neurology
Mar 03, 2011: Talecris Biotherapeutics Receives EU Orphan Drug Designation For Plasmin As Treatment For Acute Peripheral Arterial Occlusion
Feb 14, 2011: Proteo Announces Positive Ethical Opinion For Phase II Coronary Bypass Trial
Jan 25, 2011: Bristol-Myers Squibb And sanofi-aventis Announce FDA Decision To Grant Pediatric Exclusivity For PLAVIX
Jan 20, 2011: Pervasis To Present Phase I/II Clinical Study Data Of Cell Therapy Targeting PAD At Conference On Cell Therapy For Cardiovascular Diseases
Jan 19, 2011: Merck Says Additional Information Provided To Investigators In Clinical Study Of Vorapaxar
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Peripheral Arterial Disease, H1 2012
Products under Development for Peripheral Arterial Disease - Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
United Therapeutics Corporation, H1 2012
Sanofi-Aventis, H1 2012
Athersys, Inc., H1 2012
GlaxoSmithKline plc, H1 2012
Merck & Co., Inc., H1 2012
Nissan Chemical Industries, Ltd., H1 2012
CardioVascular BioTherapeutics, Inc., H1 2012
MultiGene Vascular Systems (MGVS) Ltd., H1 2012
Light Sciences Oncology, Inc., H1 2012
Talecris Biotherapeutics Holdings Corp, H1 2012
Mesoblast Ltd, H1 2012
ReNeuron Group plc, H1 2012
SYGNIS Pharma AG, H1 2012
AnGes MG, Inc., H1 2012
LTT Bio-Pharma Co., Ltd., H1 2012
Sucampo Pharmaceuticals, Inc., H1 2012
7TM Pharma A/S, H1 2012
Biolex Therapeutics, Inc., H1 2012
Proteon Therapeutics, Inc., H1 2012
Pervasis Therapeutics, Inc., H1 2012
Taiwan Liposome Company, H1 2012
Taligen Therapeutics Inc., H1 2012
Theravasc, Inc., H1 2012
Viromed Co., Ltd., H1 2012
Lee's Pharmaceutical Holdings Limited, H1 2012
miRagen Therapeutics, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Peripheral Arterial Disease Therapeutics - Drug Profile Updates
Peripheral Arterial Disease Therapeutics - Discontinued Products
Peripheral Arterial Disease Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Peripheral Arterial Disease, H1 2012
Products under Development for Peripheral Arterial Disease - Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.